@article{CJCR1379,
author = {Aiqin Gu and Chunlei Shi and Liwen Xiong and Tianqing Chu and Jun Pei and Baohui Han},
title = {Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer},
journal = {Chinese Journal of Cancer Research},
volume = {25},
number = {1},
year = {2013},
keywords = {},
abstract = {Objective: To evaluate the efficacy and safety of icotinib hydrochloride in patients with advanced non-small cell lung cancer (NSCLC).
Methods: A total of 89 patients with stage IIIB or IV NSCLC received icotinib at a dose of 125 mg administered 3 times a day. Icotinib treatment was continued until disease progression or development of unacceptable toxicity.
Results: A total of 89 patients were assessable. In patients treated with icotinib, the overall response rate (RR) was 36.0% (32/89), and the disease control rate (DCR) was 69.7% (62/89). RR and DCR were significantly improved in patients with adenocarcinoma versus non-adenocarcinoma (P<0.05). The symptom improvement rate was 57.3% (51/89), and the main symptoms improved were cough, pain, chest distress, dyspnea, and Eastern Cooperative Oncology Group performance status. The main toxic effects were rash [30/89 (33.7%)] and diarrhea [15/89 (16.9%)]. The level of toxicity was typically low.
Conclusions: The use of icotinib hydrochloride in the treatment of advanced NSCLC is efficacious and safe, and its toxic effects are tolerable.},
issn = {1993-0631}, url = {https://cjcr.amegroups.org/article/view/1379}
}